Apogee Therapeutics appoints Lisa Bollinger, MD to board of directors

Apogee Therapeutics, Inc.

Lisa Bollinger, MD elected as Class II director, effective May 28, 2024.
Bollinger brings 30+ years in drug development; most recently VP Regulatory Affairs at Merck (MRK).
She also served as VP Global Patient Safety at Amgen and 12 years at FDA.
Will serve on the Nominating and Corporate Governance Committee.
Appointment adds regulatory and safety expertise as Apogee advances two clinical programs.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Lisa L. Bollinger

Class II director

APGE · Apogee Therapeutics, Inc.

Effective: 2024-05-28
Filed: May 28, 2024, 7:59 PM ET

the board of directors (the “Board”) of Apogee Therapeutics, Inc. (the “Company”) elected Lisa L. Bollinger, M.D. to serve as a Class II director of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Lisa L. Bollinger was elected as Class II director at Apogee Therapeutics, Inc..

Action: elected
Role: Class II director

Exact text from the filing

the board of directors (the “Board”) of Apogee Therapeutics, Inc. (the “Company”) elected Lisa L. Bollinger, M.D. to serve as a Class II director of the Company

View on SEC.gov

Apogee Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-065322

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.